Current Month 2009
Article Features
  African-American Women with Advanced Breast Cancer Often Forego Vital Treatment
Breast MRI Detects Additional “Unsuspected” Cancers Not Seen on Mammography or Ultrasound
Mother-Daughter Breast Study Points Way to Earlier Cancer Risk Assessment
Research Shows Biopsy of Recurrent Breast Cancer Can Alter Treatment
Researchers Identify New Protein Important in Breast Cancer Gene’s Role in DNA Repair
Stromal Caveolin-1 Predicts Breast Cancer Prognosis
What Influences Women’s Opinions on Their Breast Surgery?
Women are 10 Times More Likely To Do Breast Self-Exams with Intervention


Protein Predicts Development of Invasive Breast Cancer in Women with DCIS

Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine. The results, published in the journal Cancer Epidemiology, Biomarkers and Prevention, may help clinicians distinguish between DCIS that requires minimal treatment and DCIS that should be treated more aggressively.

"Not all DCIS is the same," says Brian Czerniecki, MD, PhD, Co-Director of the Rena Rowan Breast Center at the University of Pennsylvania and Surgical Director of the Immunotherapy Program for the Abramson Cancer Center. "From a practical standpoint, if you know that a patient has a greater chance of invasive cancer when you're doing a lumpectomy or mastectomy, then you might want to do a sentinel node biopsy, because there is a greater chance the cancer has spread to the lymph nodes."

DCIS accounts for more than 20 percent of all breast cancer diagnoses in the United States. While many of these premalignant lesions will progress to invasive disease, clinicians currently cannot predict which women are at greatest risk.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon